Neurizon Therapeutics (ASX:NUZ) appointed Kathryn Williams as chief regulatory officer, Jeffrey Brown as chief scientific adviser, and Chris Freitag as chief medical adviser, according to a Thursday Australian bourse filing.
Williams has 20 years of experience in regulatory affairs, securing fast track and orphan designations with regulatory bodies, the filing said.
Brown also has over 20 years of experience in drug development experience in neurology programs.
Freitag is a medical doctor with nearly 30 years of medical and pharmaceutical experience focusing on oncology and rare diseases.
The company's shares rose 15% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.